|15 January, 2020

Hikma Pharmaceuticals inks deal to distribute Chiesi’s products in Egypt

Hikma will distribute eleven of Chiesi’s leading products, mainly respiratory and neonatal therapeutic products, in the Egyptian market.

Medicine in shelves in commissioning machine in pharmacy. Image used for illustrative purpose

Medicine in shelves in commissioning machine in pharmacy. Image used for illustrative purpose

Getty Images
Cairo - Mubasher: Hikma Pharmaceuticals, a global company with local presence in the US, the MENA region, and Europe, has penned a licensing and distribution agreement with Italy-headquartered Chiesi Farmaceutici, an international research-focused pharmaceutical group, to commercialise medical products in Egypt.

Under the agreement, Hikma will distribute eleven of Chiesi’s leading products, mainly respiratory and neonatal therapeutic products, in the Egyptian market. This agreement adds to the success of Hikma’s existing partnership with Cheisi in Morocco as well as its portfolio in Egypt.

Hikma’s executive vice chairman and president of MENA, Mazen Darwazah, said:“ In particular, this agreement enables us to meet the needs of a growing number of patients suffering from asthma and COPD in Egypt, and improve their access to high-quality medicines.”

Meanwhile, the CEO of Chiesi Group, Ugo Di Francesco, remarked: “This will allow us to increase the availability of our main therapeutic solutions in the respiratory and neonatology fields to Egyptian patients.”

Source: Mubasher

All Rights Reserved - Mubasher Info © 2005 - 2019 Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Business